Biomarker‐based Bayesian randomized clinical trial design for identifying a target population
Yasuo Sugitani, Satoshi Morita, Akiyoshi Nakakura et al. · Statistics in Medicine · 2023
The challenges and potential benefits of incorporating biomarkers into clinical trial designs have been increasingly discussed, in particular to develop new agents for immune-oncology or targeted cancer therapies. To more accurately identify a sensitive subpopulation of patients, in many cases, a larger sample size-and consequently higher development costs and a longer study period-might be required. This article discusses a biomarker-based Bayesian (BM-Bay) randomized clinical trial design that incorporates a predictive biomarker measured on a continuous scale with pre-determined cutoff points or a graded scale to define multiple patient subpopulations. We consider designing interim analyses with suitable decision criteria to achieve correct and efficient identification of a target patient population for developing a new treatment. The proposed decision criteria allow not only the take-in of sensitive subpopulations but also the ruling-out of insensitive ones on the basis of the efficacy evaluation of a time-to-event outcome. Extensive simulation studies are conducted to evaluate the operating characteristics of the proposed method, including the probability of correct identification of the desired subpopulation and the expected number of patients, under a wide range of clinical scenarios. For illustration purposes, we apply the proposed method to design a randomized phase II immune-oncology clinical trial.
Cited by 1 works. doi:10.1002/sim.9749
Authors
References
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
- Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
- Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
- Moving Beyond the Hazard Ratio in Quantifying the Between-Group Difference in Survival Analysis
- Center for Drug Evaluation and Research
- Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC
- The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt
- Biomarker-Adaptive Threshold Design: A Procedure for Evaluating Treatment With Possible Biomarker-Defined Subset Effect
- Speeding up the Evaluation of New Agents in Cancer